rebioin journal
OF BIOSCIENCES

ADVANCEMENTS AND EMERGING APPLICATIONS OF STEM CELL TECHNOLOGY IN REGENERATIVE MEDICINE



admin@reboin.com

www.rebioin.com

Advancements and Emerging Applications of Stem Cell Technology in Regenerative Medicine

Piyush Yadav[1], Aditya Gupta[2], Prince Kumar Singh[3]

Student, Bansal Institute of Engineering and Technology, Lucknow

Corresponding author's E-mail: yadavpiyush23052005@gmail.com

Abstract

Stem cell research stands at the forefront of modern biotechnology, presenting exceptional possibilities for regenerative therapies, disease modeling, and pharmaceutical development. In the last decade, significant progress in induced pluripotent stem cells (iPSCs), three- dimensional (3D) organoid cultures, CRISPR-enabled gene modification, and exosome-based treatments has accelerated the journey from experimental studies to clinical practice. On a global scale, integrating advanced tools such as artificial intelligence, 3D bioprinting, and next- generation bioreactor technologies has broadened the horizons of personalized medicine and tissue engineering. Nations like Japan, the United States, and China have emerged as leaders in innovation and commercialization; however, the sector continues to be influenced by ethical dilemmas, uneven regulatory frameworks, and the proliferation of unverified treatments. This paper explores the latest developments and innovations in stem cell research through a global lens, assessing key technological advances, therapeutic uses, ethical considerations, and prospects. By examining both opportunities and challenges, it emphasizes the importance of harmonized policies, cross-disciplinary partnerships, and fair access to ensure the safe and effective application of stem cell technologies worldwide.

Keywords: Stem cell research, regenerative medicine, iPSCs, 3D organoids, exosome therapy, CRISPR, biotechnology, global innovation.

1. Introduction

Stem cell research has become one of the most dynamic and influential domains in biotechnology, offering exceptional opportunities for regenerative medicine, disease modeling, and novel drug discovery. Since the landmark achievement of isolating human embryonic stem cells in 1998, the field has progressed at an extraordinary pace. A defining breakthrough occurred in 2006 with the development of induced pluripotent stem cells (iPSCs), enabling the reprogramming of adult somatic cells into a pluripotent state and effectively mitigating many of the ethical issues linked to embryonic sources. In recent years, the discipline has been transformed by a range of innovations, including CRISPR/Cas9-mediated genome editing, three-dimensional (3D) organoid systems, bioprinting technologies, artificial intelligence (AI)- driven cell analytics, and advanced bioreactor designs [1]. These advancements have broadened applications from tailored medical interventions to the engineering of complex tissues [2]. For example, 3D organoids derived from stem cells offer realistic biological models for studying organ development and disease mechanisms, while CRISPR technology allows for accurate correction of pathogenic gene variants before therapeutic use. Countries such as Japan, the United States, and China are leading global efforts in clinical trials, translational research, and commercialization, propelled by significant governmental funding and industry partnerships. However, international regulatory landscapes differ considerably—some regions maintain strict

governance, whereas others adopt more permissive approaches to stimulate innovation. Ethical challenges remain, particularly the spread of unverified stem cell treatments marketed directly to patients in jurisdictions with minimal oversight. The intersection of rapid scientific progress and complex policy concerns underscores the necessity for harmonized global regulations, stringent safety and efficacy testing, and equitable access to these emerging therapies. This paper provides a comprehensive overview of emerging trends and innovations in stem cell research worldwide, examining technological breakthroughs, clinical implications, ethical considerations, and prospective developments in this fast-evolving field [3-5].

1.1 Classification and characteristics

1.1.1 Embryonic Stem Cells (ESCs)

Embryonic stem cells are derived from the inner cell mass of the blastocyst during early embryonic development, typically at 4–5 days post-fertilization. These cells are pluripotent, capable of differentiating into all three germ layers—ectoderm, mesoderm, and endoderm— thus giving rise to nearly all cell types in the body. ESCs exhibit a high proliferation rate, maintain telomerase activity, and express specific pluripotency markers such as Oct4, Sox2, and Nanog. However, their use raises ethical concerns due to the destruction of embryos, and there is a risk of tumor formation upon transplantation. Despite challenges, they remain a cornerstone for developmental biology research [6].

1.1.2 Adult (Somatic) Stem Cells

Adult or somatic stem cells are undifferentiated cells present in specialized niches of mature tissues, such as bone marrow, skin, and liver. They are typically multipotent, giving rise to
specific cell types related to their tissue of origin, such as hematopoietic stem cells (HSCs) producing blood cells or mesenchymal stem cells (MSCs) differentiating into bone, cartilage, and fat. Their primary role is to maintain tissue homeostasis and participate in repair after injury. Adult stem cells have lower tumorigenic risk than ESCs but are limited in potency and proliferative capacity. They are commonly used in clinical therapies, especially bone marrow transplants [7].

1.1.3 Perinatal Stem Cells

Perinatal stem cells are obtained from extraembryonic tissues such as umbilical cord blood, placenta, and amniotic fluid at the time of birth. They share characteristics of both embryonic and adult stem cells, displaying high proliferative capacity and differentiation potential into mesodermal, ectodermal, and endodermal lineages. Umbilical cord blood stem cells are widely banked for potential therapeutic use because they are less immunogenic and easier to collect non-invasively. Research indicates they may be valuable for treating hematological disorders, immune deficiencies, and degenerative diseases. Perinatal tissues provide an ethically acceptable and rich source of stem cells without the controversies of ESCs [8].

1.1.4 Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells are artificially reprogrammed from differentiated adult somatic cells, such as fibroblasts, by introducing specific transcription factors—commonly Oct4, Sox2, Klf4, and c-Myc. This reprogramming, pioneered by [9], restores pluripotency, enabling these cells to differentiate into virtually any cell type. iPSCs overcome ethical concerns of ESCs while offering patient-specific cell sources for regenerative medicine, disease modeling, and drug screening. However, challenges include low reprogramming efficiency, genomic instability, and potential tumorigenicity. Ongoing research focuses on improving safety and reproducibility to make iPSC-based therapies clinically viable.

2. Technological Advancements and Methodologies

Over the past two decades, stem cell research has experienced remarkable progress driven by advanced technologies that enhance isolation, characterization, and application potential. The development of induced pluripotent stem cells (iPSCs) [10] revolutionized the field by enabling the reprogramming of

adult somatic cells into a pluripotent state through the introduction of specific transcription factors. This innovation bypasses ethical issues associated with embryonic stem cells (ESCs) while allowing patient-specific cell line creation for disease modeling and regenerative medicine.

Advances in cell culture systems have been equally significant. Three-dimensional (3D) culture platforms, such as organoids and spheroids, better mimic the native microenvironment compared to traditional two-dimensional cultures, thus improving cell differentiation fidelity [11]. The use of bioreactors facilitates large-scale stem cell expansion under controlled conditions, maintaining genetic stability and differentiation potential.

Genome editing technologies, particularly CRISPR-Cas9, have transformed stem cell research by enabling precise genetic modifications. This allows for the correction of disease-causing mutations in patient-derived iPSCs, facilitating the development of personalized therapeutic strategies [12]. Combined with high-throughput screening, CRISPR-edited stem cells are instrumental in drug discovery and toxicity testing.

Another methodological advancement is single-cell RNA sequencing (scRNA-seq), which provides detailed insights into heterogeneity within stem cell populations, revealing rare subpopulations and novel differentiation pathways [13]. This is complemented by advanced imaging techniques, such as live-cell fluorescence microscopy, which track stem cell fate and lineage commitment in real time.

Tissue engineering approaches integrate stem cells with biomaterial scaffolds, promoting targeted tissue regeneration. Bioprinting technologies allow the spatial arrangement of stem cells within bioinks to construct complex, functional tissue structures [14]. Additionally, microfluidic "organ-on-a-chip" platforms simulate physiological conditions, enabling more predictive preclinical testing of stem cell-based therapies.

Collectively, these advancements are accelerating the transition of stem cell research from bench to bedside. The integration of iPSC technology, genome editing, 3D culture, and biofabrication not only enhances scientific understanding but also brings regenerative medicine closer to addressing currently incurable diseases.

3. Clinical and Therapeutic Applications

Stem cells hold transformative potential in modern medicine due to their ability to self-renew and differentiate into multiple cell types. In clinical practice, their application spans regenerative medicine, immunotherapy, and tissue engineering. Hematopoietic stem cells (HSCs), sourced from bone marrow, peripheral blood, or umbilical cord blood, have been extensively used in treating hematological disorders such as leukemia, lymphoma, and severe aplastic anemia. The transplantation of HSCs reconstitutes the patient's blood and immune systems, offering curative outcomes in many cases [15].

In regenerative therapies, mesenchymal stem cells (MSCs) have gained prominence due to their immunomodulatory properties and capacity to differentiate into osteocytes, chondrocytes, and adipocytes. Clinical trials have demonstrated their efficacy in cartilage repair, osteoarthritis treatment, and spinal cord injury recovery [16]. Additionally, MSCs are being explored for treating graft-versus-host disease (GVHD), where they suppress alloreactive immune responses and enhance tissue repair [17].

Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), offer broader therapeutic possibilities because they can differentiate into nearly all somatic cell types. iPSCs, generated from adult somatic cells via reprogramming, circumvent ethical issues associated with ESCs and allow patient-specific therapy. They are being investigated for applications such as generating dopaminergic neurons for Parkinson's disease, cardiomyocytes for heart failure, and insulin-producing β-cells for diabetes mellitus [18].

In ophthalmology, stem cell therapy has shown success in treating limbal stem cell deficiency, a condition leading to corneal opacity and vision loss. Transplantation of cultured limbal epithelial cells has restored sight in numerous patients, representing a significant clinical milestone [19]. Furthermore, retinal pigment epithelium (RPE) derived from iPSCs or ESCs is under investigation for age-related macular degeneration treatment.

Cancer treatment has also benefited from stem cell technologies. Beyond bone marrow transplantation, engineered stem cells are used as delivery vehicles for anti-tumor agents, enhancing drug targeting

while minimizing systemic toxicity [20].
Despite their promise, challenges remain, including the risk of teratoma formation from pluripotent cells, immune rejection, and ensuring controlled differentiation. Advances in gene editing (e.g., CRISPR-Cas9) and biomaterial scaffolds are being integrated to improve safety, precision, and functional integration of stem cell-derived tissues. Overall, stem cells are reshaping therapeutic strategies across multiple medical domains, with ongoing research expected to expand their clinical relevance in the coming decades.

4. Current Trends and Breakthrough Applications

Stem cell research has transformed remarkably over the past two decades, transitioning from exploratory biological curiosity to a dynamic field with tangible therapeutic potential. The defining characteristic of stem cells—the ability to self-renew and differentiate into specialized cell types—has been leveraged in both experimental and clinical domains, driving innovations in regenerative medicine, disease modeling, and tissue engineering.

5. Current Trends in Stem Cell Research

5.1 Induced Pluripotent Stem Cells (iPSCs)

The reprogramming of adult somatic cells into pluripotent states using transcription factors (e.g., OCT4, SOX2, KLF4, c-MYC) has redefined accessibility to patient-specific stem cells. Unlike embryonic stem cells (ESCs), iPSCs circumvent ethical controversies while retaining pluripotency, enabling patient-matched disease models and autologous transplantation with minimal immune rejection risk [21]. Advancements now focus on non-integrating delivery systems to reduce genomic instability during reprogramming.

5.2 Organoid Technology

Three-dimensional organoids derived from ESCs, iPSCs, or adult stem cells have emerged as physiologically relevant models for human tissues such as the brain, liver, gut, and kidney. These organoids recapitulate organ-specific architecture and cellular diversity, enabling studies on development, pathophysiology, and drug responses. CRISPR-mediated genome editing within organoids further enhances disease modeling precision [22].

5.3 Stem Cell-derived Immunotherapies

Hematopoietic stem cell (HSC) transplantation remains a cornerstone in oncology and immunodeficiency treatment. More recently, iPSC-derived natural killer (NK) cells and chimeric antigen receptor (CAR)-modified immune cells are being developed for off-the-shelf cancer immunotherapies. This approach aims to overcome limitations in donor availability and immune compatibility.



Figure 1: Clinical and Therapeutic Application of Stem Cells.

5.4 Single cell Multi-omics

Single-cell RNA sequencing (scRNA-seq) and integrated multi-omics approaches are unraveling the molecular heterogeneity within stem cell populations. These insights are guiding refined differentiation protocols and enabling the identification of rare subpopulations with superior regenerative potential.

6. Breakthrough Applications

6.1 Regenerative Medicine

Stem cells are actively investigated for treating neurodegenerative disorders such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal cord injuries. In recent trials, dopaminergic neurons derived from iPSCs have been transplanted into Parkinson's patients, showing improved motor function without tumor formation risks. Similarly, mesenchymal stem cells (MSCs) are being tested for cartilage repair and myocardial regeneration, supported by encouraging preclinical evidence.

6.2 Ophthalmology

Stem cell-based retinal pigment epithelium (RPE) transplants have shown promise in age- related macular degeneration (AMD). Early-phase clinical trials demonstrate partial restoration of visual acuity, suggesting stem cells could halt or reverse vision loss in degenerative retinal diseases.

6.3 Diabetes Treatment

iPSC-derived pancreatic beta cells have been developed to restore insulin production in type 1 diabetes patients. Encapsulation strategies protect transplanted cells from autoimmune destruction while allowing nutrient and insulin exchange. Vertex Pharmaceuticals recently reported human trials with notable improvements in insulin independence.

6.4 Precision Oncology

Patient-derived organoids are enabling personalized cancer therapy screening. By testing multiple chemotherapeutic and targeted agents on tumor organoids, oncologists can identify optimal treatment regimens before administering them to the patient, minimizing trial-and- error risks in clinical care.

6.5 Gene and Stem Cell Synergy

The convergence of CRISPR-Cas9 gene editing with stem cell technology is opening avenues for curing monogenic disorders. For example, HSCs edited ex vivo to correct β-globin gene mutations have successfully restored functional hemoglobin production in β-thalassemia and sickle cell disease patients [24].

6.6 COVID-19 and Immune Modulation

MSC-based therapies have been explored for severe COVID-19 cases, aiming to reduce cytokine storm-induced lung damage. Early studies suggest reduced inflammation and improved oxygenation, though large-scale trials are still required for validation.

6.7 Tissue and Organ Bioengineering

The combination of 3D bioprinting with stem cells has progressed toward generating vascularized, functional tissue constructs. While full organ printing remains a long-term goal, advancements in printing cartilage, skin, and vascularized tissue patches mark a substantial leap toward transplantable engineered organs.

7. Challenges and Future Directions

Despite significant progress, challenges remain in scaling production, ensuring genetic stability, and preventing teratoma formation. Standardized differentiation protocols are crucial for clinical translation,

as is rigorous long-term safety monitoring. Regulatory frameworks must evolve to accommodate rapidly advancing stem cell-based therapies without compromising patient safety.

In the future, integrating artificial intelligence with stem cell biology could accelerate predictive modeling for differentiation outcomes and optimize personalized treatment strategies. Combining real-time imaging, bioprinting precision, and immune-tolerant universal donor cells could make regenerative therapies globally accessible**.**

The application of stem cells in regenerative medicine offers immense potential; however, several scientific, ethical, and practical challenges hinder their widespread adoption. One major limitation is the risk of tumorigenicity, especially with pluripotent stem cells, as uncontrolled cell proliferation can lead to teratomas [25]. Immune rejection remains another concern, as transplanted cells may trigger host immune responses, requiring immunosuppressive therapy [26]. Standardization in differentiation protocols is also challenging, often resulting in heterogeneous cell populations with unpredictable therapeutic outcomes [27].

Ethical controversies, particularly surrounding embryonic stem cells, continue to influence policy and funding decisions [28]. Furthermore, large-scale production of clinically viable stem cells demands stringent quality control, increasing costs, and limiting accessibility [29]. Long- term safety data is still insufficient, making regulatory approval complex and time-consuming. Additionally, the microenvironment of transplanted cells plays a critical role in their survival and integration, yet replicating the natural niche remains difficult [30].

Overcoming these challenges requires advances in gene editing, scaffold engineering, and immune tolerance strategies, alongside ethical consensus and global regulatory harmonization to ensure safe and equitable clinical translation of stem cell therapies.

8. Future Outlook and Research Directions

8.1 Emerging Potential of Stem Cells

Stem cells hold remarkable potential to transform healthcare through their ability to regenerate tissues and treat previously incurable conditions. Induced pluripotent stem cells (iPSCs) are gaining attention as they can be derived from a patient's cells, bypassing ethical concerns linked to embryonic stem cells and minimizing immune rejection risks [31].

8.2 Technological Innovations

Advancements such as 3D bioprinting aim to create functional tissues and eventually fully functional organs, addressing the critical shortage of donors [32]. Another innovation, organoid technology, allows the growth of miniature tissue systems in laboratories, providing precise disease models and improving personalized drug testing [33].

8.3 Integration with Modern Tools

Gene editing tools like CRISPR-Cas9 enable targeted correction of genetic disorders before cell transplantation, offering precise therapeutic solutions [34]. Nanotechnology integration can improve targeted delivery of biochemical signals, enhancing stem cell survival and controlled differentiation in the body**.**

8.4 Translational and Clinical Pathways

Future progress depends on standardized production methods, AI-assisted culture optimization, and biomimetic scaffolds that recreate natural stem cell environments. These advances could expand applications to neurodegenerative, autoimmune, and metabolic disorders.

9. Conclusion

Stem cell research is reshaping the landscape of biotechnology by offering solutions that go beyond symptom management to actual tissue regeneration. The development of induced pluripotent stem cells (iPSCs) has significantly reduced reliance on embryonic sources, addressing both ethical and

immunological barriers (Takahashi & Yamanaka, 2006). Innovations like 3D bioprinting and organoid technology are enabling the creation of complex, functional tissue systems that can be tailored for patient-specific applications (Murphy & Atala, 2014; Lancaster & Knoblich, 2014). Meanwhile, precision genome-editing tools such as CRISPR-Cas9 allow targeted correction of genetic abnormalities, potentially halting diseases before clinical onset (Kim et al., 2020). However, the journey toward widespread clinical use is hindered by challenges in large-scale production, genomic stability, and ensuring long-term integration of transplanted cells. Addressing these issues through interdisciplinary collaboration, strict quality control, and ethical governance will be essential to move stem cell therapy from experimental trials into safe, routine medical treatments that redefine modern healthcare**.**

Conflict of Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Cyranoski, D. (2019). Stem-cell pioneer banks on Japan's relaxed regulations. *Nature, 565*(7738), 544.
2. Doudna, J. A., & Charpentier, E. (2014). He new frontier of genome engineering with CRISPR-Cas9. *Science, 346*(6213), 1258096.
3. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science, 282*(5391), 1145–1147.
4. Lancaster, M. A., & Knoblich, J. A. (2014). Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science, 345*(6194), 1247125.
5. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures. *Cell, 126*(4), 663–676.
6. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science, 282*(5391), 1145–1147.
7. Weissman, I. L., Anderson, D. J., & Gage, F. H. (2001). Stem and progenitor cells: Origins, phenotypes, lineage commitments, and transdifferentiations. *Annual Review of Cell and Developmental Biology, 17*, 387–403.
8. Pappa, K. I., & Anagnou, N. P. (2009). Novel sources of fetal stem cells: Where do they fit on the developmental continuum? *Regenerative Medicine, 4*(3), 423–433.
9. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell, 126*(4), 663–676.
10. Takahashi, K., & Yamanaka, S. (2006). *Cell, 126*(4), 663–676.
11. Lancaster, M. A., & Knoblich, J. A. (2014). *Science, 345*(6194), 1247125.
12. Li, M., Belmonte, J. C. I., & De Los Angeles, A. (2020). Stem cell pluripotency and transcription factor networks. *Nature Reviews Genetics, 21*(7), 415–433.
13. Tanay, A., & Regev, A. (2017). Scaling single-cell genomics from phenomenology to mechanism. *Nature Biotechnology, 35*(8), 711–720.
14. Murphy, S. V., & Atala, A. (2014). 3D bioprinting of tissues and organs. *Nature Biotechnology, 32*(8), 773–785.
15. Appelbaum, F. R. (2007). Hematopoietic-cell transplantation at 50. *New England Journal of Medicine, 357*(15), 1472–1475.
16. Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A.I. (2019). Mesenchymal stem cell perspective: Cell biology to clinical progress. *NPJ Regenerative Medicine*.
17. Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., … & Ringden, O. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft- versus-host disease.

The Lancet, 371(9624), 1579–1586.
18. Takahashi, K., & Yamanaka, S. (2016). A decade of induced pluripotent stem cells: Self- renewal to transplantation. *Cell, 166*(6), 1526–1546.
19. Rama, P., Matuska, S., Paganoni, G., Spinelli, A., De Luca, M., & Pellegrini, G. (2010). Limbal stem-cell therapy and long-term corneal regeneration. *New England Journal of Medicine, 363*(2), 147–155.
20. Pawelczyk, E., Jordan, E. K., Balakumaran, A., Chaudhry, A., Gormley, N., Smith, M.,& Frank, J. A. (2008). In vivo tumorigenicity testing of genetically engineered human mesenchymal stem cells. *Molecular Therapy, 16*(2), 284–294.
21. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell, 126*(4), 663–676.
22. Lancaster, M. A., & Knoblich, J. A. (2014). Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science, 345*(6194), 1247125.
23. Murphy, S. V., & Atala, A. (2014). 3D bioprinting of tissues and organs. *Nature Biotechnology, 32*(8), 773–785.
24. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., … & Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β- thalassemia. *New England Journal of Medicine, 384*(3), 252–260.
25. Amariglio, N., Hirshberg, A., Scheithauer, B. W., Cohen, Y., Loewenthal, R., Trakhtenbrot, L., … & Rechavi, G. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. *PLoS Medicine, 6*(2), e1000029.
26. Taylor, C. J., Bolton, E. M., Pocock, S. J., Sharples, L. D., Pedersen, R. A., & Bradley, J.A. (2011). Banking on human embryonic stem cells: Estimating the number of donor cell lines needed for HLA matching. *The Lancet, 366*(9502), 2019–2025.
27. Trounson, A., & McDonald, C. (2015). Stem cell therapies in clinical trials: Progress and challenges. *Cell Stem Cell, 17*(1), 11–22.
28. Lo, B., & Parham, L. (2009). Ethical issues in stem cell research. *Endocrine Reviews, 30*(3), 204–213.
29. Mason, C., & Dunnill, P. (2008). A brief definition of regenerative medicine. *Regenerative Medicine, 3*(1), 1–5.
30. Discher, D. E., Mooney, D. J., & Zandstra, P. W. (2009). Growth factors, matrices, and forces combine and control stem cells. *Science, 324*(5935), 1673–1677.
31. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures. *Cell, 126*(4), 663–676.
32. Murphy, S. V., & Atala, A. (2014). 3D bioprinting of tissues and organs. *Nature Biotechnology, 32*(8), 773–785.
33. Lancaster, M. A., & Knoblich, J. A. (2014). Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science, 345*(6194), 1247125.
34. Kim, J., Koo, B.-K., & Knoblich, J. A. (2020). Human organoids: Model systems for human biology and medicine. *Cell Stem Cell, 27*(5), 705–731.

rebioin journal
OF BIOSCIENCES

ADVANCEMENTS AND EMERGING APPLICATIONS OF STEM CELL TECHNOLOGY IN REGENERATIVE MEDICINE





Plot no 977, GMS Road, near Balliwala Flyover, opposite Cubic Plaza,
Dehradun, Uttarakhand 248001

admin@reboin.com

www.rebioin.com